NCT05383716View on ClinicalTrials.gov

Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 8, 2023

Study Completion Date

December 31, 2027

Conditions
Non Small Cell Lung CancerNeoadjuvant TherapyImmune Checkpoint Inhibitor
Interventions
DRUG

Pembrolizumab

Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER